Quality Management

Development Status and Prospect of National Drug Packaging Material Reference Standards

Expand
  • National Institutes of Food and Drug Control, Beijing 100050 , China

Online published: 2022-09-21

Abstract

Objective: To introduce the development history, current situation of national drug packaging material reference standards, and explore the development direction of reference standards for drug packaging materials in China. Methods: Through the analysis and comparison methods, the existing problems of the national drug packaging material reference standards were summarized, and the reasonable suggestions for the development of drug packaging material reference standards were put forward. Results: Since the release of the national drug packaging material reference standards 5 years ago, it has played a great role in controlling the quality of drug packaging materials and improving the inspection capabilities of testing institutions, while it needs to be improved in terms of coverage and promotion. Conclusion: The national drug packaging material reference standards are important guarantees for the smooth implementation of the 2020 edition of the "Chinese Pharmacopoeia" and the 2015 edition of "National Standard for Drug Packaging Materials". It is necessary to further play the role of "weight" in the national standards for the drug packaging material reference standards. The currently issued drug packaging material reference standards cover a small number of additives, and each category could not be fully covered. There are limitations in actual testing, and more varieties of research and development are urgently needed.

Cite this article

Han Xiaoxu, Zhao Xia, Yang Huiying, Sun Huimin . Development Status and Prospect of National Drug Packaging Material Reference Standards[J]. Chinese Pharmaceutical Affairs, 2022 , 36(9) : 990 -1001 . DOI: 10.16153/j.1002-7777.2022.09.004

References

[1] 陈亚飞,肖新月,李波.国外药品标准物质质量管理介绍及对我国的启示[J].中国药事,2013,27(12):1258-1261.
[2] 国家市场监督管理总局计量司.市场监管总局关于加强标准物质建设和管理的指导意见[J].轻工标准与质量,2021(6):19-22.
[3] 朱红激.浅谈药品标准物质标准样品[J].化学试剂,2017,39(4):379-384.
[4] 王丹丹,金宏,俞辉,等.国内外药品包装材料标准的比较[J].中国药品标准,2013,14(3):212-214.
[5] 谢兰桂,赵霞,孙会敏.塑料薄膜氧气透过量测定能力验证研究[J].中国药事,2019,33(4):422-428.
[6] 谢兰桂,赵霞,孙会敏.塑料薄膜水蒸气透过量测定能力验证[J].塑料科技,2019,47(6):103-108.
[7] 谢兰桂,赵萌,项新华,等.回顾分析药品包装材料阻隔性测定能力验证保障药品质量安全[J].中国药事,2021,35(11):1225-1231.
[8] 中华人民共和国药典:四部[S].2020:547-548.
[9] 中国食品药品检定研究院.国家药包材标准[S].2015:123-126.
[10] 马玲云,刘明理,马双成.国家药品标准物质的发展历程与现状[J].中国药学杂志,2012,47(13):1017-1021.
[11] 王学芬,陈祖坚,闫超.中国与欧美药品包装材料相容性研究规范[J].广州化工,2014,42(5):31-33,50.
[12] 国家药品监督管理局.国家药监局第14号关于发布化学药品与弹性体密封件相容性研究技术指导原则(试行)的通告[S].2018:4.
[13] 国家药品监督管理局.国家药监局第40号关于发布化学药品注射剂与药用玻璃包装容器相容性研究技术指导原则(试行)的通告[S].2015:7.
[14] 周亚菊,姜骏,朱燕,等.药包材气体透过量测定方法标准现状及展望[J].中国药品标准,2022,23(1):1-4.
[15] 谢兰桂,赵霞,孙会敏.基于定制试验设计法的聚丙烯输液瓶密度测量相关影响因素研究[J].药物分析杂志,2019,39(7):5.
[16] 国家药典委员会,中国医药包装协会.欧美日药典药包材标准选编[M].北京:化学工业出版社,2019:1-27.
[17] 刘言.药品包装材料与药物相容性研究的现状及展望 [J].天津药学,2013,25(6):56-59.
[18] 王丹丹,俞辉.从药典视角谈构建中国药包材标准体系的建议[J].中国现代应用药学,2021,38(5):537-540.
[19] Unite States Pharmacopoeia:<661.1>Plastic Materials of Construction[S].2021:542-554.
[20] European Pharmacopoeia:3.1.13 Plastic Additives[S].2020:441-445.
[21] 陈超,王丹丹,程磊,等.《中华人民共和国药典》 2020年版和国外药典的药包材标准体系概述[J].中国医药工业杂志,2021,52(2):267-271.
[22] Japanese Pharmacopoeia:7.02 Test Methods for Plastic Containers [S].2016:179-184.
[23] 陈蕾,康笑博,宋宗华,等.《中国药典》2020年版第四部药用辅料和药包材标准体系概述[J].中国药品标准,2020,21(4):307-312.
[24] 国家药品监督管理局药审中心.国家药监局药审中心通告第33号化学药品注射剂生产所用的塑料组件系统相容性研究技术指南[S].2020:2.
[25] 国家食品药品监督管理局.国食药监局267号关于印发化学药品注射剂与塑料包装材料相容性研究技术指导原则(试行)的通知[S].2012:9.
[26] 孟伟娟,邱迎昕,俞培富,等.我国药包材相关法规及卤化丁基药用胶塞与药物相容性分析方法研究进展 [J].药物分析杂志,2021,41(11):1860-1867.
[27] 张静,陈会明.邻苯二甲酸酯类增塑剂的危害及监管现状[J].现代化工,2011,31(12):1-6.
[28] 秦青.聚氯乙烯药品包装材料和容器中邻苯二甲酸酯类增塑剂的监管现状分析[J].中国包装,2016(4):78-80.
[29] 林黄静,吴莹,张毅兰.三层共挤膜输液袋中抗氧剂168降解产物DBP的提取和测定[J].中国医药工业杂志,2014,45(7):677-680.
[30] 方旻,林晓娟,周建栋,等.塑料输液包装材料中抗氧剂降解产物对药液的迁移研究[J].中国医疗器械信息,2016,23(1):50-52.
[31] 杨岳平,胡长鹰,钟怀宁,等.抗氧剂168的降解及其降解产物的测定[J].现代食品科技,2016,32(6):304-309.
Options
Outlines

/